Product How it works Pricing Blog FAQ About Contact
Orchestra BioMed

Orchestra BioMed (NASDAQ: OBIO) revenue

Orchestra BioMed reported revenue of $33.5m for fiscal 2025, 1,169.2% more than in fiscal 2024 ($2.6m). Since fiscal 2022 its revenue has grown by 847.7%, an average growth of 111.6% a year.

Fiscal 2025 is the highest of the 4 fiscal years on record for Orchestra BioMed. The biggest drop was in fiscal 2023, −21.9%.

Revenue, in millions of US dollars3.520222.820232.6202433.52025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$33.5m+1,169.2%−$51.8m−154.7%
2024$2.6m−4.4%−$64.3m−2,437.5%
2023$2.8m−21.9%−$51.5m−1,866.2%
2022$3.5m—−$32.7m−924.3%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Orchestra BioMed revenue compared with its sector

By revenue for its latest fiscal year, Orchestra BioMed ranks 347th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Orchestra BioMed, 1,169.2%.

RankCompanyRevenueRevenue growth
345thX4 Pharmaceuticals$35.1m1,250.5%
346thPrecision Biosciences$34.3m−50.1%
347thOrchestra BioMed$33.5m1,169.2%
348thStereotaxis$32.4m20.3%
349thEyePoint$31.4m−27.5%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Orchestra BioMed

How much revenue did Orchestra BioMed make in fiscal 2025?
Orchestra BioMed reported revenue of $33.5m for fiscal 2025, compared with $2.6m in fiscal 2024.
How much has the revenue of Orchestra BioMed grown?
Between fiscal 2022 and fiscal 2025 it went from $3.5m to $33.5m: 847.7% more, an average growth of 111.6% a year.
What was the best year for revenue at Orchestra BioMed?
Of its last 4 fiscal years, fiscal 2025, with $33.5m.
Where does Orchestra BioMed rank in its sector by revenue?
It ranks 347th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Orchestra BioMed come from?
From the annual report (Form 10-K) that Orchestra BioMed files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Orchestra BioMed files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Orchestra BioMed: the Orchestra BioMed page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.